LINC01638 regulates miR-128/PDK1 to promotes cell proliferation and drug resistance in ovarian cancer

This study aims to explore the functional mechanism of LINC01638 in ovarian cancer (OC). The OC cell proliferation, viability and colony formation were respectively measured using CCK-8, MTT and colony formation assay. The cell cycle and apoptosis were both assessed using flow cytometry. Online bioinformatics tools were performed to predict the downstream gene of LINC01638. RNA pull down experiment and luciferase reporter assay were processed to verify the predictions. The expression of LINC01638, miR-128-3p and PDK1 in OC tissues and cells were detected using qRT-PCR and ISH analysis. The expressions of cisplatin-related proteins were determined by western blot. OC mice model was constructed to carry out in vivo experiment. LINC01638 was highly expressed in OC tissues and cells, and its high expression was related to poor OC prognosis. LINC01638 knockdown inhibited cell proliferation, colony formation and cisplatin resistance, promoted cell apoptosis and induced cell cycle arrest in OC cells. LINC01638 knockdown suppressed tumor growth, proliferation and cisplatin resistance and enhanced apoptosis in vivo . LINC01638 directly targeted miR-128-3p/PDK1 in OC cells. LINC01638 affected OC cell proliferation, survival and cisplatin resistance via combing miR-128-3p and promoting PDK1 expression.